Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.98
+0.08 (1.01%)
Dec 5, 2025, 4:00 PM EST - Market closed
Gyre Therapeutics Revenue
Gyre Therapeutics had revenue of $30.56M in the quarter ending September 30, 2025, with 19.92% growth. This brings the company's revenue in the last twelve months to $107.27M, up 2.13% year-over-year. In the year 2024, Gyre Therapeutics had annual revenue of $105.76M, down -6.78%.
Revenue (ttm)
$107.27M
Revenue Growth
+2.13%
P/S Ratio
6.50
Revenue / Employee
$185,259
Employees
579
Market Cap
725.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 105.76M | -7.69M | -6.78% |
| Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
| Dec 31, 2022 | 102.29M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGYRE News
- 4 weeks ago - Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis - GlobeNewsWire
- 7 weeks ago - Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
- 3 months ago - Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker - Benzinga
- 3 months ago - Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - GlobeNewsWire